SEC FORM 3

SEC FORM 3SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Li Jiaqiang

(Last)

(First)

(Middle)

ONE INTERNATIONAL PL

44TH FLOOR

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/17/2026

3. Issuer Name and Ticker or Trading Symbol
SINOVAC BIOTECH LTD [ SVA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common shares, par value $0.001 per share	18,515,315	I	By 1Globe Capital LLC, CDH Utopia Limited and the others⁽¹⁾⁽²⁾⁽³⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. Represented (i) 6,812,855 Common shares, par value $0.001 per share, of the Issuer (the "Common Shares") held directly by 1Globe Capital LLC; (ii) 6,000,000 Common Shares held by CDH Utopia Limited (the "Subject Shares"), (x) over 70% of which 1Globe Biomedical (Hong Kong) Company Limited posseses the voting rights and (y) over all the which 1Globe Biomedical (Hong Kong) Company Limited posseses the voting rights over certain financial upside; and (iii) 5,702,460 Common Shares held by relatives or related parties of the Reporting Person.

2. 1Globe Biomedical (Hong Kong) Company Limited is the sole member of 1Globe Capital LLC and may be deemed to beneficially own the Common Shares held by 1Globe Capital LLC. 1Globe Biomedical (Hong Kong) Company Limited may be deemed to beneficially own the Subject Shares held by CDH Utopia Limited. The Reporting Person is the Chairman of each of 1Globe Capital LLC and 1Globe Biomedical (Hong Kong) Company Limited. The Reporting Person may be deemed the ultimate beneficial owner of the Common Shares held by 1Globe Capital LLC, 1Globe Biomedical (Hong Kong) Company Limited and his relatives.

3. The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported shares for purposes of Section 16 or for any other purposes.

	/s/ Jiaqiang Li	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

SEC Form 3 filed by new insider Li Jiaqiang